Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + doxorubicin + epirubicin + vincristine + prednisone
- Development stage
- Unknown
- Lead developer
- Baxter
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination is a chemotherapy regimen that includes **cyclophosphamide** (an alkylating agent), **doxorubicin** and **epirubicin** (both anthracyclines), **vincristine** (a vinca alkaloid), and **prednisone** (a corticosteroid). It is used in the treatment of various cancers, including lymphomas. The mechanism of action involves DNA damage (alkylating agents and anthracyclines), microtubule disruption (vinca alkaloids), and immunosuppression (corticosteroids).
02
Targets
DNATOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))Microtubule
Beyond the preview
Go deeper on cyclophosphamide + doxorubicin + epirubicin + vincristine + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + doxorubicin + epirubicin + vincristine + prednisone.